Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université du Québec à Montréal

$17,500.00

Sensitivity of [18F]FEOBV used with positron emission tomography to identify patients with Alzheimer’s Disease.

FY 2013-14

Summary
The [18F] fluoroethoxybenzovesamicol ([18F]FEOBV) is a radioactive compound recently synthesized by Dr Bedard’s team at the Montreal Neurological Institute (MNI), in order to be used for brain imaging, using PET. The [18F]FEOBV is believed to label cholinergic terminals of the brain, which are known both to be affected in Alzheimer's disease (AD), and to correlate well with clinical symptom severity. Therefore, [18F]FEOBV might be able to detect AD as well as to quantify its severity, because of its specific sensitivity to the AD cholinergic neuropathology. Recent results obtained in both rodents and primates, are concordant with such an assumption. The aim of my research project is to further verify this hypothesis in human. My project‘s aim is to study the properties of ([18F] FEOBV) , a derivative of Vesamicol, as a promising radio-tracer, and biomarker to quantify the integrity of cholinergic neurons in the human brain, to facilitate the differential diagnosis of Alzheimer’s Disease (AD), and to quantify the severity (stages) of AD over a given period. More specifically, the hypotheses are the following: • [18F]FEOBV used with PET will be able to distinguish patients with AD (mild to moderate) from normal subjects; • In AD, [18F]FEOBV used with PET will be correlated with the neuropsychological measures of disease severity; • Brain topography of [18F]FEOBV reduction in AD will be concordant with the known neuropathology of the cholinergic system in this disease, that is mostly in the basal forebrain, hippocampus and cerebral cortex, but not in the brainstem and thalamus. I would be able to verify the existence of any correlations between the severity of AD measured by any clinical evaluations and those measured by PET scan using the 2 existing bio-tracers ([18F]FDG,[11C]PiB) and the promising [18F] FEOBV. And lastly, testing the sensitivity of [18F] FEOBV in comparison with [18F]FDG to quantify the progression of AD in a period of 1 year.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311729
Name
Aghourian-Namagerdy Meghmik
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Sensitivity of [18F]FEOBV used with positron emission tomography to identify patients with Alzheimer’s Disease.
Programtype2
Studentship Programs
Orgnameinp2
Université du Québec à Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acetylcholine; Ad Biomarker; Ad Related Dimentia; Alzheimer`S Disease Ad; Beta-Amyloid Protein; Cholinergic Terminals In Brain; Diagnosis Of Ad; Neuropathology Of The Cholinergic System; Pet Scan; [18f] Fluoroethoxybenzovesamicol ([18f]Feobv)
Abstract
The [18F] fluoroethoxybenzovesamicol ([18F]FEOBV) is a radioactive compound recently synthesized by Dr Bedard’s team at the Montreal Neurological Institute (MNI), in order to be used for brain imaging, using PET. The [18F]FEOBV is believed to label cholinergic terminals of the brain, which are known both to be affected in Alzheimer's disease (AD), and to correlate well with clinical symptom severity. Therefore, [18F]FEOBV might be able to detect AD as well as to quantify its severity, because of its specific sensitivity to the AD cholinergic neuropathology. Recent results obtained in both rodents and primates, are concordant with such an assumption. The aim of my research project is to further verify this hypothesis in human. My project‘s aim is to study the properties of ([18F] FEOBV) , a derivative of Vesamicol, as a promising radio-tracer, and biomarker to quantify the integrity of cholinergic neurons in the human brain, to facilitate the differential diagnosis of Alzheimer’s Disease (AD), and to quantify the severity (stages) of AD over a given period. More specifically, the hypotheses are the following: • [18F]FEOBV used with PET will be able to distinguish patients with AD (mild to moderate) from normal subjects; • In AD, [18F]FEOBV used with PET will be correlated with the neuropsychological measures of disease severity; • Brain topography of [18F]FEOBV reduction in AD will be concordant with the known neuropathology of the cholinergic system in this disease, that is mostly in the basal forebrain, hippocampus and cerebral cortex, but not in the brainstem and thalamus. I would be able to verify the existence of any correlations between the severity of AD measured by any clinical evaluations and those measured by PET scan using the 2 existing bio-tracers ([18F]FDG,[11C]PiB) and the promising [18F] FEOBV. And lastly, testing the sensitivity of [18F] FEOBV in comparison with [18F]FDG to quantify the progression of AD in a period of 1 year.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Aghourian-Namagerdy, Meghmik
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~
Université du Québec à Montréal - $17,500 Grant (2013… | Canada Spends